Treatment for Parkinson Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Utah, Salt Lake City, UT
Parkinson Disease+3 More
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

Levodopa is a precursor of dopamine and is the treatment of choice to treat the motor symptoms of Parkinson's disease (PD); however, the effect of levodopa on cardiovascular autonomic function in PD is poorly understood. Orthostatic hypotension has been documented as a potential side effect of levodopa. As a result, clinicians may be reluctant to prescribe levodopa in patients with PD with neurogenic orthostatic hypotension (PD+OH), which leads to suboptimal management of motor symptoms. On the other hand, other studies failed to show any clear relationship between levodopa and orthostatic hypotension in patients with PD. Important limitations of prior studies include the lack of detailed investigation of baroreflex cardiovagal and sympathetic noradrenergic functions and the fact that the same patients were not tested on and off levodopa. The investigators propose to investigate the effects of levodopa on cardiovascular autonomic function in patients with PD+OH and PD without neurogenic orthostatic hypotension (PD-OH) by performing standardized autonomic testing in the same patients on and off levodopa.

Eligible Conditions

  • Parkinson Disease
  • Orthostatic Hypotension

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Outcome measures will be assessed at 1 year

Year 1
Modified composite autonomic severity score (CASS) [range 0-7; higher scores = worse outcome].
Validated index of baroreflex cardiovagal function
Validated index of sympathoneural function

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

40 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: outcome measures will be assessed at 1 year

Trial Background

Prof. Guillaume Lamotte, Assistant Professor
Principal Investigator
University of Utah
Closest Location: University of Utah · Salt Lake City, UT
Photo of ut university of utah  1Photo of ut university of utah  2Photo of ut university of utah  3
2006First Recorded Clinical Trial
9 TrialsResearching Parkinson Disease
670 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.